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introduction: Breast cancer is frequently diagnosed, yet variation remains in terms of 
practice patterns in presurgical workup. We sought to determine factors associated with 
this variation.
Methods: An anonymous web-based survey was distributed to surgeons regarding 
their practices. Statistical analyses were conducted using SPSS.
results: A total of 253 surgeons responded to the survey. 17.0% were in academic 
practice, 37.5% were hospital employed, and 41.5% were in private practice. 53.3% 
claimed that >50% of their practice was breast related. Surgeons were asked how 
often they would use various tests in the workup of an otherwise healthy asymptomatic 
patients, presenting with a non-palpable mammographic abnormality and a core needle 
biopsy showing invasive breast cancer. 23.5% stated that they always would obtain a 
breast ultrasound, 17.2% stated that they never would. 12.8% stated that they never 
order a breast MRI; 4.1% always would. Workup of patients did not vary significantly 
based on number of years in practice nor practice setting. However, those whose prac-
tice was >50% breast were more likely to state that they would always order a breast 
ultrasound (32.5 vs. 12.9%, p < 0.001), and less likely to state that they would never 
order a breast MRI (3.4 vs. 25.8%, p < 0.001). However, the proportions of surgeons 
who would always order a breast MRI were similar in the two groups (3.4 and 3.2%, 
respectively).
conclusion: These data highlight the lack of uniformity in the workup of asymptomatic 
patients presenting with non-palpable breast cancers, pointing to potential areas for 
improving value by minimizing variability.
Keywords: variation, breast cancer, workup, tests, guideline adherence
TaBle 1 | Demographic and practice characteristics of respondents.
Factor number of respondents (%)
Age (years)a
30–40 38 (15.0)
41–50 54 (21.3)
51–60 76 (30.0)
61–70 54 (21.3)
>70 16 (6.3)
Years in practiceb
<5 26 (10.3)
5–10 31 (12.3)
11–20 53 (20.9)
21–30 78 (30.8)
>30 52 (20.6)
Proportion of practice breast related (%)c
<10 25 (9.9)
10–25 60 (23.7)
26–50 22 (8.7)
51–75 27 (10.7)
76–99 34 (13.4)
100 74 (29.2)
Practice settingd
Private practice 105 (41.5)
Hospital employed 95 (37.5)
Academic 43 (17.0)
aAge group not specified by 15 (5.9%) respondents.
bYears in practice not specified by 13 (5.1%) respondents.
cProportion of practice that is breast related not specified by 11 (4.3%) respondents.
dPractice setting not specified by 10 (4.0%) respondents.
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inTrODUcTiOn
Breast cancer is the leading malignancy affecting women, with 
over 232,000 people being diagnosed with this disease annually 
in the United States (1). Given the ubiquity of screening mam-
mography, particularly in more developed parts of the world, 
many women will present with non-palpable early stage disease. 
Faced with a plethora of potential adjunct imaging modalities, 
there is significant variability in the workup of these patients. 
Evidence for the cost-effectiveness and/or incremental benefit 
of these additional imaging techniques is limited. While clinical 
practice will vary based on individual patient characteristics, the 
goal of this study was to determine, given a hypothetical scenario, 
how often surgeons felt they would order various tests. While 
guidelines advocate for or against some of these techniques in 
all circumstances, they are far less prescriptive for others. We, 
therefore, sought to determine the variation in practices among 
surgeons in their preoperative workup of otherwise healthy 
asymptomatic patients presenting with non-palpable early stage 
breast cancer.
MaTerials anD MeThODs
An anonymous web-based survey was distributed to surgeons 
via the American College of Surgeons Communities. The 
Communities is an online platform, with a variety of discussion 
forums geared toward individual surgeons’ interests and demo-
graphics. Our survey was posted in the General, Breast Surgery 
and International forums. We asked surgeons to “tell us how 
[they] work up patients who present to [them] with a newly diag-
nosed breast cancer. For otherwise healthy asymptomatic patients, 
presenting with a non-palpable mammographic abnormality and a 
core biopsy showing invasive breast cancer, [surgeons were asked] 
how often [they] perform each of [a prespecified list of] tests as part 
of [their] presurgical work-up.” For each option, they could choose 
from the following options: never, infrequently (<25%), sometimes 
(25–75%), often (>75%), or always. No identifiable personal 
information was collected. Given the nature of the survey, it was 
deemed exempt by the Human Investigations Committee of Yale 
University.
Non-parametric bivariate statistical analyses using Fisher’s 
exact and likelihood ratio tests for categorical variables were 
conducted using IBM SPSS Statistics (Version 21). As this was a 
survey that was deemed to be hypothesis generating rather than 
hypothesis testing, a power analysis and/or sample size calculation 
was not indicated. The survey was posted on an online platform 
and, therefore, it is impossible to determine the denominator for 
a potential response rate.
resUlTs
Two hundred fifty three surgeons from eight countries, primar-
ily in North America, responded to the survey. The majority 
(n = 234) came from the United States. Their demographic and 
practice characteristics are shown in Table  1. Surgeons were 
asked how frequently they would order each of a series tests in 
the setting of an otherwise healthy asymptomatic woman who 
presented with a non-palpable mammographic abnormality and 
a core needle biopsy result of invasive ductal carcinoma.
additional Breast imaging
In terms of additional breast imaging, there was significant 
variation in practice. 17.2% of respondents stated that they would 
“never” order a breast ultrasound in this circumstance, while 23.5% 
stated that they “always” would. The distribution of responses 
were fairly evenly distributed between the five possible responses 
of never, infrequently (<25%), sometimes (25–75%), often (>75%), 
and always. In terms of breast MRI, nearly three times as many 
respondents reported that they would never order this test in this 
circumstance (12.8%) as those who stated that they always would 
(4.1%). These distributions are shown in Figure 1. There was a 
significant correlation between the use of breast ultrasound and 
breast MRI, with 40.5% of the 37 surgeons who stated that they 
“never” order breast ultrasound also noting that they would never 
use breast MRI, and 28.6% of the seven surgeons who stated that 
they would “always” order breast MRI also stating that they would 
always order a breast ultrasound (p < 0.001).
There was no correlation between surgeon age, number of 
years in practice, type of practice setting and geographic loca-
tion, and the propensity to order additional breast imaging 
(Table 2). The only demographic or practice variable associated 
with the use of breast ultrasound and/or MRI was the proportion 
of practice that was breast related. Respondents whose practice 
was >50% breast related were significantly more likely to report 
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FigUre 1 | Distribution of additional breast imaging. Proportion of respondents reporting their likelihood of ordering either breast ultrasound (blue bars) or 
breast MRI (orange bars).
TaBle 2 | Factors correlating with the use of further breast imaging.
Factor Breast Us Breast Mri
no. (%) reporting “always” p-value no. (%) reporting “always” p-value
Age (years) 0.200 0.581
30–40 10 (29.4) 2 (5.7)
41–50 12 (23.5) 1 (2.1)
51–60 12 (18.2) 4 (5.8)
61–70 13 (27.7) 1 (2.1)
>70 4 (26.7) 1 (6.7)
Years in practice 0.590 0.326
<5 7 (30.4) 2 (8.3)
5–10 9 (33.3) 0 (0)
11–20 10 (21.7) 1 (2.2)
21–30 11 (16.4) 5 (7.5)
>30 13 (27.1) 1 (2.2)
% Practice breast related 0.005 <0.001
<10 2 (9.1) 0 (0)
10–25 7 (13.7) 2 (3.8)
26–50 3 (15.0) 1 (5.0)
51–75 6 (27.3) 1 (4.3)
76–99 9 (32.1) 0 (0)
100 24 (34.3) 3 (4.3)
Practice setting 0.440 0.194
Private practice 20 (21.7) 4 (4.3)
Hospital employed 19 (21.8) 4 (4.7)
Academic 11 (29.7) 0 (0)
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that they would “always” order a breast ultrasound (32.5 vs. 
12.9%, p <  0.001). While the proportion of those who stated 
that they would “always” order a breast MRI was not remarkably 
different between those with greater than vs. less than or equal 
to 50% breast related (3.4 vs. 3.2%, respectively), those with 
≤50% breast-related practices were significantly more likely to 
“never” order a breast MRI in this circumstance (25.8 vs. 3.4%, 
p < 0.001).
Metastatic Workup
In terms of tests that may be ordered as part of a metastatic workup, 
the majority of respondents stated that they would “never” order a 
CT chest, CT abdomen/pelvis, ultrasound of the liver, bone scan, 
CT/MRI brain, or PET scan in asymptomatic patients presenting 
with non-palpable mammographically detected (presumed early 
stage) disease. The distribution of responses for each of these tests 
is shown in Figure 2.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
CT chest
CT abdomen/pelvis
US liver
CT/MRI brain
Bone scan
PET scan
CT chest CTabdomen/pelvis US liver CT/MRI brain Bone scan PET scan
Never 56% 58% 71% 71% 59% 62%
Infrequently (< 25%) 36% 33% 25% 25% 29% 31%
Somemes (25-75%) 4% 3% 2% 1% 5% 5%
Oen (> 75%) 2% 1% 1% 1% 3% 1%
Always 3% 4% 1% 1% 5% 1%
Never Infrequently (< 25%) Somemes (25-75%) Oen (> 75%) Always
FigUre 2 | Distribution of tests typically used for the evaluation of distant metastatic disease. Proportion of respondents reporting their likelihood of 
ordering CT scan chest, CT scan abdomen/pelvis, Ultrasound liver, CT/MRI brain, Bone scan, PET scan.
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There were neither demographic nor practice-related variables 
that significantly correlated with the use of additional imaging to 
rule out metastatic disease among surgeons. Interestingly, those 
who practiced outside of the United States were significantly more 
likely to report that they would “always” obtain an ultrasound of 
the liver (13.3 vs. 0.5%, p = 0.001), and a bone scan (26.7 vs. 2.5%, 
p = 0.004) than their American counterparts. Rates of ordering 
CT or PET scans did not vary significantly based on geographic 
location.
Not surprisingly, surgeons who stated that they only obtain a 
metastatic workup in patients presenting with clinically stage III 
disease were less likely to report “always” obtaining a CT chest (0 
vs. 5.9%, p = 0.008), CT abdomen/pelvis (0 vs. 7.9%, p = 0.010), 
or a bone scan (0 vs. 7.9%, p =  0.004) in the situation of an 
asymptomatic patient presenting with non-palpable, mammo-
graphically detected cancer.
chest X-rays and “routine” Blood Work
Surgeons’ use of “routine” blood work and chest X-rays (CXRs) 
as part of the preoperative workup for these patients was also 
elicited. We did not expressly ask surgeons whether these tests 
were being done to rule out metastatic disease or whether these 
were being done as part of their perioperative management. 
Blood work, such as complete blood counts (CBC), comprehen-
sive metabolic panel (CMP)/electrolytes, and liver function tests 
(LFTs) were frequently performed, with 56.6, 53.3, and 48.9% 
of surgeons stating that they would “always” do each of these 
tests, respectively. The use of CXR was much more variable, with 
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29.9% of respondents stating that they would “never” order a 
CXR in this setting and 33.9% stating that they “always” would.
There were few characteristics that were associated with the 
use of these tests. Respondents whose practices were entirely 
breast surgery were more likely to report “never” ordering CXR 
(44.1 vs. 23.3%, p = 0.005), CBC (18.8 vs. 6.0%, p = 0.020), CMP/
electrolytes (24.6 vs. 6.6%, p = 0.003), or LFTs (30.4 vs. 11.2%, 
p = 0.011). In general, rates did not vary by surgeon age, practice 
setting nor geographic location; however, those who had been in 
practice for >30 years were also significantly less likely to state 
that they would “always” order LFTs than those who had been in 
practice for <5 years (42.6 vs. 72.0%, p = 0.027).
DiscUssiOn
Every year, over 232,000 women will be diagnosed with breast 
cancer; the majority of these at early stage (1). It is estimated that 
the number of patients diagnosed with breast cancer will increase 
significantly by 2030 and, therefore, excess expenditure without 
added benefit in these patients is worthy of consideration. We 
found that there was significant variation among surgeons in the 
preoperative workup of relatively straight-forward early breast 
cancer patients.
additional Breast imaging
In terms of additional imaging, there seemed to be an equal 
distribution of respondents who stated that they would either 
“never,” “rarely,” “sometimes,” “often,” or “always” order a breast 
ultrasound. NCCN guidelines recommend that breast ultrasound 
be used “as necessary” as an adjunct to mammography in the 
workup of patients with early stage breast cancer (2). The term “as 
necessary” is not highly prescriptive, and may explain wide vari-
ations in practice. Some authors have argued that the addition of 
whole-breast ultrasound may find clinically and mammographi-
cally occult cancers that may impact the patient’s care, particularly 
when multicentric (3–5), and may also improve margin clearance 
(6). However, the utility and cost-effectiveness of routine use of 
whole-breast ultrasound has not been established. It is likely 
that breast ultrasound may be useful in some circumstances but 
not in all. Still, we found that nearly a quarter of surgeons who 
responded to the survey stated that they would always order a 
breast ultrasound, and those who were in solely breast-related 
practices were more likely to claim that they do so. This raises 
the issue of whether breast ultrasound is over-utilized in these 
practices, and one may speculate that breast surgeons with ready 
access to ultrasonography may be more likely to either order or 
perform breast ultrasound because of its immediate availability 
rather than because the outcome of the test would truly change 
their management.
Similarly, the utility of MRI as a routine preoperative measure 
has been questioned. While it is clear that MRI may find additional 
disease that may be otherwise mammographically occult, it is 
unclear whether such disease would be clinically significant. For 
example, it is well-known that MRI can find multicentric disease 
in up to 30% of patients (7). Yet, clinical trials like the NSABP 
B-06, which were done in the pre-MRI era, found no difference 
in survival between those undergoing partial vs. total mastectomy, 
leading some to question the impact of undetected multicentric 
disease on this outcome (8). Indeed, an individual level meta-
analysis found that MRI had no impact on overall or disease-free 
survival (9). While some have argued that preoperative MRI may 
allow better evaluation of extent of disease, thereby yielding better 
margin clearance, there have been two randomized controlled 
trials that have produced level 1 evidence to the contrary (10, 
11). While the majority of surgeons in our study stated that they 
would “never” or “infrequently” use preoperative breast MRI in 
the situation of an asymptomatic patient presenting with a mam-
mographically detected, non-palpable invasive ductal carcinoma, 
4.1% of surgeons stated that they “always” would despite clear 
evidence of the lack of utility for this modality as standard routine 
practice (12).
Interestingly, we found a relationship between the propensity 
to order a preoperative MRI and that to order breast ultrasound, 
such that 28.6% of patients who stated that they would “always” 
order a breast MRI would also “always” order a breast ultrasound. 
It is unclear whether surgeons who responded in this way would 
“always” order an ultrasound to further evaluate findings on 
breast MRI. If this was the case, however, this would assume that 
they always found additional lesions found on MRI warrant-
ing further ultrasonographic evaluation, or that they routinely 
ordered ultrasound upfront “just in case” the MRI found such 
lesions. Perhaps more likely, these respondents would “always” 
order an MRI to further evaluate patients after breast mammo-
gram and ultrasound. However, Mariscotti et al. found minimal 
incremental benefit of adding MRI to patients evaluated with 
mammography and ultrasound (13).
In a study of women diagnosed with breast cancer in the 
SEER-Medicare database, Lee et al. found that 28.5% of patients 
would have additional breast imaging studies (beyond mam-
mography). These data are similar to our findings. While we did 
not specifically evaluate costs, as these would be different at dif-
ferent institutions around the country and the globe, the effect of 
additional breast imaging on the cost of care is not insignificant. 
Lee et al. noted that “the average per capita cost for a diagnostic 
workup was $360.89 in 2004, about half of which was attributable 
to relevant radiology, diagnostic mammography, and other breast 
imaging studies” (14). Given the ubiquity of breast cancer, these 
data highlight the need to carefully evaluate variation in the use of 
breast imaging studies, and the utility and the cost-effectiveness 
of such practices, particularly given our findings that surgeons 
with a greater proportion of breast-related practices were more 
likely to order further breast imaging.
Metastatic Workup
The majority of surgeons surveyed followed ASCO/NCCN 
guidelines (2, 15) and stated that they would “never” order a 
metastatic workup in asymptomatic patients with mammo-
graphically detected, non-palpable breast cancers. However, the 
proportion of surgeons who stated that they would “never” order 
tests that would be considered part of a metastatic workup ranged 
from 56% (for CT chest) to 71% (for either ultrasound of the liver 
or CT/MRI of the brain). This leaves a significant minority of 
surgeons who would at least infrequently order these tests in 
patients who were otherwise asymptomatic with a non-palpable 
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mammographically detected lesion, which would presumably 
be early stage disease. Our finding that up to 5% of respondents 
would “always” order tests, such as CT scans or bone scans, in 
patients with presumably early stage disease is concerning, par-
ticularly given that the cost of detecting metastatic disease per 
patient screened in this population is nearly infinite (16).
We have previously reported the data in which we found that 
7.3% of surgeons “always” performed a metastatic workup prior 
to surgery (17), even though the probability of finding metastatic 
disease in patients with early stage breast cancer is <1–2% (18). 
Not only is avoiding a metastatic workup in asymptomatic 
patients who present with early stage disease a recommenda-
tion of ASCO’s “Choosing Wisely” campaign and the NCCN 
guidelines, but also such a policy is endorsed internationally. For 
example, the European guidelines for quality assurance in breast 
cancer screening and diagnosis stated that “a complete diagnostic 
work-up to detect metastases is unnecessary in the majority of 
patients with newly diagnosed breast cancer whereas it may be 
indicated for patients with advanced disease” (19). The European 
Society for Medical Oncology also noted that, aside from physical 
examination, “other tests are not routinely recommended unless 
locally advanced or when symptoms suggestive of metastases are 
present” (20). Practice guidelines from Canada similarly state 
that “routine bone scanning, liver ultrasonography and chest 
radiography are not indicated before surgery” (21).
chest X-rays and “routine” Blood work
Over a third of surgeons stated that they would “always” order a 
CXR as part of their preoperative workup in a patient with early 
breast cancer. It is unclear as to whether this was done to rule 
out metastatic disease or whether it was done to stratify patients’ 
operative risk. From an oncologic standpoint, NCCN guidelines 
do not recommend CXR in this setting (2). Furthermore, the 
American Society of Anesthesiologists and other professional 
organizations do not recommend routine CXR as part of the 
perioperative workup of asymptomatic patients (22, 23).
While NCCN guidelines continue to recommend routine 
blood work, including a CBC and liver function studies, the 
true value of these studies in terms of detecting conditions or 
metastatic disease that would change management is unclear. 
Nonetheless, the majority of surgeons surveyed stated that they 
would “always” perform these tests in accordance with guide-
lines. Of note, the NCCN guidelines do not recommend CMP/
electrolytes; yet, 53.3% of surgeons stated that they “always” 
ordered these tests. Some may argue that these tests are being 
ordered as part of a perioperative workup, rather than as a result 
of the breast cancer diagnosis. However, the American Society of 
Anesthesiologists recommends against routine preoperative test-
ing (22); rather “preoperative electrolyte and creatinine testing 
should be reserved for patients at risk of electrolyte abnormalities 
or renal impairment” (24).
Studies from around the world have found an over-utilization 
of “routine” blood work in the perioperative setting without a 
concomitant benefit in terms of changing management (25–27). 
Issa et al. found that of the 1075 preoperative tests done in 200 
patients in Brazil, 55.8% were not indicated (27). Interestingly, 
they found that surgeons, more than anesthesiologists, order tests 
as a matter of routine resulting in a net increase in the cost per 
patient of 33.6% (27). Similarly, in a study of 1496 patients in 
Thailand, Siriussawakul et al. found that only 12.1% of patients 
had preoperative workups that were in accordance with guide-
lines, with CMP/electrolytes being the most commonly ordered 
unnecessary test (26). In the UK, Phoenix et al. estimated that 
inappropriate preoperative blood work resulted in an extrapo-
lated cost of £11.2 million per year (28). In the United States, 
a similar trend is noted. St. Clair et al. found that only 17% of 
preoperative CMPs were indicated. The cost of the unnecessary 
CMP in the 197 patients in whom it was ordered without indica-
tion in their study was estimated to be $9,589 based on Medicare 
reimbursement and $41,670 based on institutional charges (25).
study limitations
This study should be considered in the context of its limita-
tions. To begin with, this is a survey of surgeons. As such, it 
is limited by the subjective responses of surgeons. We had no 
way of objectively validating surgeons’ responses, nor could we 
assess the outcomes of variations in practice pattern for indi-
vidual patients. However, this survey asked surgeons to describe 
their usual practice, and how often they would order tests in 
an otherwise healthy asymptomatic patient presenting with 
a non-palpable cancer found as a result of a mammographic 
abnormality. Second, the surgeons who responded to this survey 
were self-selected, and we had no way of determining a response 
rate, nor understanding whether the cohort of surgeons who 
responded to the survey were systematically different from those 
who did not. Having said this, the demographics of the surgeons 
who responded are diverse and seem to reflect, in general, the 
practice of breast surgery in the United States. Furthermore, we 
did not query surgeons who stated that they would “always” 
order studies that are not recommended as a matter of guide-
lines as to whether they (a) knew that their practice was not 
indicated and (b) why they continued to advocate for such tests. 
It is possible that surgeons order such tests due to patient insist-
ence, medical malpractice concerns, or institutional practices 
that do not comply with guidelines.
cOnclUsiOn
Despite these limitations, this study highlights variation in 
practice in the workup of early stage breast cancer patients. As 
healthcare costs continue to rise at an unsustainable pace, there is 
increasing focus on evidence-based cost-effective care. Our study, 
which found wide variation in the diagnostic and preoperative 
workup of breast cancer patients, is particularly concerning 
given the prevalence of this disease. Despite guidelines, surgeons 
will often order tests that may not be needed, highlighting the 
need for ongoing education, and the potential for tremendous 
cost-savings if variation could be minimized. This study should 
call attention to the over-utilization of tests that add minimal 
incremental benefit. Professional organizations and institutions 
should re-evaluate their current policies and engage in further 
education of surgeons to “choose wisely” when ordering workups 
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for their otherwise healthy newly diagnosed asymptomatic breast 
cancer patients.
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